A&D Pharma reports 33% growth, credits restructuring

A&D Pharma, the biggest pharmaceutical group on the Romanian market, posted 150 million euros in turnover in the first three months of the year, up 33% (in euros) from last year’s Q1.

The company has outpaced the pharmaceutical market by more than 10% during this interval; according to data of research company IMS, the overall market grew by 21.4% in euros (17.3% in RON).

“The steps taken last year were felt into the first three months of 2010,” said Robert Popescu, CEO of A&D Pharma. The CEO explained that last year the company restructured the business lines and streamlined its sales force, which was reflected in the turnover, but did not say what specific measures helped the company attain such growth in the context of difficult economic conditions.

The group operates via three business lines: distribution (Mediplus), marketing & sales (which mainly promotes products of foreign companies with no operations on the Romanian market) and retail (Sensiblu drugstore chain).